- Home
- LSTA vs OCX Comparison
LSTA vs OCX Comparison
Compare LSTA & OCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSTA
- OCX
- Stock Information
- Founded
- LSTA 1980
- OCX 2009
- Country
- LSTA United States
- OCX United States
- Employees
- LSTA N/A
- OCX N/A
- Industry
- LSTA Misc Health and Biotechnology Services
- OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- LSTA Health Care
- OCX Health Care
- Exchange
- LSTA Nasdaq
- OCX Nasdaq
- Market Cap
- LSTA 31.2M
- OCX 35.1M
- IPO Year
- LSTA N/A
- OCX N/A
- Fundamental
- Price
- LSTA $2.51
- OCX $2.56
- Analyst Decision
- LSTA Strong Buy
- OCX Buy
- Analyst Count
- LSTA 1
- OCX 3
- Target Price
- LSTA $15.00
- OCX $4.42
- AVG Volume (30 Days)
- LSTA 60.2K
- OCX 83.3K
- Earning Date
- LSTA 02-27-2025
- OCX 11-12-2024
- Dividend Yield
- LSTA N/A
- OCX N/A
- EPS Growth
- LSTA N/A
- OCX N/A
- EPS
- LSTA N/A
- OCX N/A
- Revenue
- LSTA N/A
- OCX $709,000.00
- Revenue This Year
- LSTA N/A
- OCX N/A
- Revenue Next Year
- LSTA N/A
- OCX $106.34
- P/E Ratio
- LSTA N/A
- OCX N/A
- Revenue Growth
- LSTA N/A
- OCX N/A
- 52 Week Low
- LSTA $2.19
- OCX $1.92
- 52 Week High
- LSTA $4.20
- OCX $3.48
- Technical
- Relative Strength Index (RSI)
- LSTA 40.33
- OCX 65.73
- Support Level
- LSTA $2.51
- OCX $2.21
- Resistance Level
- LSTA $2.66
- OCX $2.60
- Average True Range (ATR)
- LSTA 0.19
- OCX 0.20
- MACD
- LSTA -0.01
- OCX 0.06
- Stochastic Oscillator
- LSTA 17.50
- OCX 93.89
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
About OCX Oncocyte Corporation
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.